Published in Am J Respir Crit Care Med on October 19, 2006
COPD Assessment and Management Bundle Versus Usual Care | NCT01833026
Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA (2008) 6.24
Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J (2007) 4.27
Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax (2013) 3.62
Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med (2011) 2.30
Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2012) 1.95
Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med (2012) 1.85
Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis (2010) 1.51
Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a multicenter cohort study. Mayo Clin Proc (2014) 1.42
Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med (2009) 1.37
The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res (2013) 1.37
Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2007) 1.25
Patient-reported dyspnea in COPD reliability and association with stage of disease. Chest (2009) 1.23
Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clin Epidemiol (2011) 1.21
Overtreatment of COPD with inhaled corticosteroids--implications for safety and costs: cross-sectional observational study. PLoS One (2013) 1.18
Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial. BMJ Open (2012) 1.13
Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatr (2010) 1.01
Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J Chron Obstruct Pulmon Dis (2013) 1.01
Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc (2008) 0.99
Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids? Am J Respir Crit Care Med (2015) 0.98
Determinants of spirometry use and accuracy of COPD diagnosis in primary care. J Gen Intern Med (2011) 0.97
Glucocorticoid insensitivity as a future target of therapy for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2010) 0.88
Inhaled Corticosteroids Increase the Risk of Pneumonia in Patients With Chronic Obstructive Pulmonary Disease: A Nationwide Cohort Study. Medicine (Baltimore) (2015) 0.86
The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD. Int J Chron Obstruct Pulmon Dis (2010) 0.85
Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. Int J Chron Obstruct Pulmon Dis (2009) 0.84
The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease. Respir Res (2010) 0.84
Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective. Br J Clin Pharmacol (2014) 0.84
Long-term therapy in COPD: any evidence of adverse effect on bone? Int J Chron Obstruct Pulmon Dis (2009) 0.83
Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis. Int J Chron Obstruct Pulmon Dis (2014) 0.82
Avoiding mistakes in calculating the number needed to treat in severe COPD. Am J Respir Crit Care Med (2007) 0.82
Relationship between the use of inhaled steroids for chronic respiratory diseases and early outcomes in community-acquired pneumonia. PLoS One (2013) 0.82
Randomized Trials Built on Sand: Examples from COPD, Hormone Therapy, and Cancer. Rambam Maimonides Med J (2012) 0.82
Elevated placenta growth factor predicts pneumonia in patients with chronic obstructive pulmonary disease under inhaled corticosteroids therapy. BMC Pulm Med (2011) 0.81
A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother (2015) 0.81
Mortality in COPD: inevitable or preventable? Insights from the cardiovascular arena. COPD (2008) 0.80
Are COPD patients with pneumonia who are taking inhaled corticosteroids at higher risk of dying? Eur Respir J (2011) 0.80
Is 'GOLD' standard for the management of COPD in clinical practice? Drugs Context (2012) 0.79
Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease. NPJ Prim Care Respir Med (2016) 0.79
Exaggeration of treatment benefits using the "event-based" number needed to treat. CMAJ (2008) 0.78
Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease-The Shifting Treatment Paradigm. COPD (2015) 0.78
Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD. Int J Chron Obstruct Pulmon Dis (2012) 0.78
Abrupt withdrawal of inhaled corticosteroids does not result in spirometric deterioration in chronic obstructive pulmonary disease: Effect of phenotyping? Ann Thorac Med (2012) 0.78
THE PARADOXICAL EFFECT ON PNEUMONIA OF CHRONIC INHALED CORTICOSTEROIDS. Clin Pulm Med (2013) 0.78
Chronic obstructive pulmonary disease lost in translation: Why are the inhaled corticosteroids skeptics refusing to go? Ann Thorac Med (2013) 0.77
Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 microg versus salmeterol in severe COPD patients. Int J Chron Obstruct Pulmon Dis (2010) 0.77
Effects of inhaled corticosteroids on pneumonia severity and antimicrobial resistance. Respir Care (2013) 0.77
Optimizing safety of COPD treatments: role of the nurse practitioner. J Multidiscip Healthc (2013) 0.77
Inhaled corticosteroids (ICS) and risk of mycobacterium in patients with chronic respiratory diseases: a meta-analysis. J Thorac Dis (2014) 0.76
Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy. Respir Res (2015) 0.76
Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respir Res (2016) 0.76
Association of Inhaled Corticosteroids with Incident Pneumonia and Mortality in COPD Patients; Systematic Review and Meta-Analysis. COPD (2015) 0.75
Hospitalizations with severe COPD. Am J Respir Crit Care Med (2007) 0.75
Metabolic Effects Associated with ICS in Patients with COPD and Comorbid Type 2 Diabetes: A Historical Matched Cohort Study. PLoS One (2016) 0.75
The risk and outcomes of pneumonia in patients on inhaled corticosteroids. Pulm Pharmacol Ther (2015) 0.75
Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Pulm Med (2015) 0.75
The "Towards a Revolution in COPD Health" study: Comparing treatment strategies. Can Fam Physician (2008) 0.75
Evaluation of pharmacotherapy of obstructive airway diseases in the Montenegrin outpatient care: comparison with two Scandinavian countries. Multidiscip Respir Med (2012) 0.75
On the correct statistical analysis of exacerbation rates in clinical trials. Am J Respir Crit Care Med (2007) 0.75
Inhaled corticosteroids for chronic obstructive pulmonary disease: a status report. Am J Respir Crit Care Med (2007) 0.75
Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.75
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med (2011) 7.92
An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest (2003) 3.19
FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J (2013) 2.87
Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation. J Immunol (2005) 1.94
Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest (2006) 1.84
Detection of obstructive sleep apnoea by an electronic nose. Eur Respir J (2012) 1.66
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63
Comparison of two devices and two breathing patterns for exhaled breath condensate sampling. PLoS One (2011) 1.45
Handling of and preferences for available dry powder inhaler systems by patients with asthma and COPD. J Aerosol Med Pulm Drug Deliv (2008) 1.40
TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers (2005) 1.32
Allergic airway inflammation inhibits pulmonary antibacterial host defense. J Immunol (2006) 1.31
Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res (2010) 1.31
The discovery of α1-antitrypsin and its role in health and disease. Respir Med (2011) 1.30
Peripheral arterial tonometry, oximetry and actigraphy for ambulatory recording of sleep apnea. Physiol Meas (2004) 1.22
Microbial DNA induces a host defense reaction of human respiratory epithelial cells. J Immunol (2004) 1.18
National survey of guideline-compliant COPD management among pneumologists and primary care physicians. COPD (2006) 1.17
The anti-microbial peptide LL-37 inhibits the activation of dendritic cells by TLR ligands. Int Immunol (2006) 1.13
The antimicrobial peptide LL-37 modulates the inflammatory and host defense response of human neutrophils. Eur J Immunol (2010) 1.12
Brain-derived neurotrophic factor (BDNF) contributes to neuronal dysfunction in a model of allergic airway inflammation. Br J Pharmacol (2004) 1.12
Seasonal distribution of COPD exacerbations in the Prevention of Exacerbations with Tiotropium in COPD trial. Chest (2013) 1.09
Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. COPD (2010) 1.06
Guideline-based survey of outpatient COPD management by pulmonary specialists in Germany. Int J Chron Obstruct Pulmon Dis (2012) 1.04
Chronic obstructive pulmonary disease and premature aging. Am J Respir Crit Care Med (2007) 1.02
Dynamics of heart rate and sleep stages in normals and patients with sleep apnea. Neuropsychopharmacology (2003) 1.02
Exposure of differentiated airway epithelial cells to volatile smoke in vitro. Respiration (2004) 1.00
Nonrandom variability of respiration during sleep in healthy humans. Sleep (2005) 1.00
Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respir Res (2013) 0.98
Comparison of exhaled breath condensate pH using two commercially available devices in healthy controls, asthma and COPD patients. Respir Res (2009) 0.94
Whole-body vibration therapy in intensive care patients: A feasibility and safety study. J Rehabil Med (2016) 0.94
Identification of individuals with alpha-1-antitrypsin deficiency by a targeted screening program. Respir Med (2007) 0.93
Opportunities and challenges in the genetics of COPD 2010: an International COPD Genetics Conference report. COPD (2011) 0.93
Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease--a randomized, multicenter, double-blind, placebo-controlled study. BMC Pulm Med (2014) 0.91
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study. Respir Res (2009) 0.91
Different Training-Induced Skeletal Muscle Adaptations in COPD Patients with and without Alpha-1 Antitrypsin Deficiency. Respiration (2016) 0.91
Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency. Respir Res (2009) 0.91
A practical guide to bioelectrical impedance analysis using the example of chronic obstructive pulmonary disease. Nutr J (2011) 0.88
Acute and chronic effects of smoking on inflammation markers in exhaled breath condensate in current smokers. Respiration (2009) 0.88
Alpha-1 antitrypsin is elevated in exhaled breath condensate and serum in exacerbated COPD patients. Respir Med (2011) 0.88
Dose-dependent recruitment of CD25+ and CD26+ T cells in a novel F344 rat model of asthma. Am J Physiol Lung Cell Mol Physiol (2007) 0.87
Efficacy of indacaterol in the treatment of patients with COPD. Prim Care Respir J (2011) 0.86
Inhibition of NF-kappaB mediated inflammation by siRNA expressed by recombinant adeno-associated virus. J Virol Methods (2004) 0.86
Effects of dipeptidyl peptidase-4 inhibition in an animal model of experimental asthma: a matter of dose, route, and time. Physiol Rep (2013) 0.86
Alpha1-antitrypsin deficiency - diagnostic testing and disease awareness in Germany and Italy. Respir Med (2013) 0.85
Discrimination between COPD patients with and without alpha 1-antitrypsin deficiency using an electronic nose. Respirology (2011) 0.85
Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. Orphanet J Rare Dis (2013) 0.85
Ambient temperature impacts on pH of exhaled breath condensate. Respirology (2009) 0.84
Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. Int J Chron Obstruct Pulmon Dis (2009) 0.84
Benefits of whole body vibration training in patients hospitalised for COPD exacerbations - a randomized clinical trial. BMC Pulm Med (2014) 0.83
Impact of different definitions of airflow limitation on the prevalence of chronic obstructive pulmonary disease in the general population. Respiration (2010) 0.82
Imatinib-associated pulmonary alveolar proteinosis. Am J Med (2003) 0.82
The EvA study: aims and strategy. Eur Respir J (2012) 0.81
Cell-specific modulation of surfactant proteins by ambroxol treatment. Toxicol Appl Pharmacol (2005) 0.81
Krüppel-like zinc finger proteins in end-stage COPD lungs with and without severe alpha1-antitrypsin deficiency. Orphanet J Rare Dis (2012) 0.80
Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe. Respir Med (2012) 0.80
Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2010) 0.80
Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naïve patients. Respir Med (2012) 0.80
Detection of air trapping in chronic obstructive pulmonary disease by low frequency ultrasound. BMC Pulm Med (2012) 0.80
Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma. Pharmacoeconomics (2005) 0.79
Tracheostomy and related host-pathogen interaction are associated with airway inflammation as characterized by tracheal aspirate analysis. Respir Med (2008) 0.79
[Budesonide/formoterol maintenance and reliever therapy. A new treatment approach for adult patients with asthma]. Med Klin (Munich) (2008) 0.78
Regional differences in prediction models of lung function in Germany. Respir Res (2010) 0.78
Future of chronic obstructive pulmonary disease management. Expert Rev Respir Med (2012) 0.77
Preselection of patients at risk for COPD by two simple screening questions. Respir Med (2010) 0.77
Is there a role for antiinflammatory treatment in COPD? COPD (2009) 0.77
Recombinant Sendai virus for efficient gene transfer to human airway epithelium. Exp Lung Res (2004) 0.77
A randomized clinical trial to assess the influence of a three months training program (gym-based individualized vs. calisthenics-based non-invidualized) in COPD-patients. Respir Res (2014) 0.77
Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs (2009) 0.77
Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial. Eur Respir J (2012) 0.77
Sex differences in alpha-1-antitrypsin deficiency lung disease-analysis from the German registry. COPD (2015) 0.77
[Intermediate care units and noninvasive ventilation]. Med Klin (Munich) (2006) 0.76
[Clinical value of forced expiratory volume in 1 s (FEV1) in chronic obstructive pulmonary disease]. Med Klin (Munich) (2009) 0.76
Correction: Comparison of Two Devices and Two Breathing Patterns for Exhaled Breath Condensate Sampling. PLoS One (2016) 0.75
Inhaled long-acting β-agonists versus anticholinergics in older patients with chronic obstructive pulmonary disease. Ann Intern Med (2011) 0.75
Pulmonary abscess with bacteremia in a young man. CMAJ (2004) 0.75
[The German Respiratory Society's Guideline for the Diagnosis and Treatment of Patients with Acute and Chronic Cough]. Med Klin (Munich) (2004) 0.75
[44th Congress of the German Pneumology Society, 26-9 March 2003 in Munich. News in Pneumology--section events of the GPS]. Pneumologie (2003) 0.75
[Bronchodilators in chronic obstructive pulmonary disease (COPD)]. Med Klin (Munich) (2005) 0.75
C-Flex technology: effects on breathing parameters and inspiratory flow limitation. Respiration (2008) 0.75
In vitro validation of a Respimat® adapter for delivery of inhaled bronchodilators during mechanical ventilation. J Aerosol Med Pulm Drug Deliv (2011) 0.75
Lichenoid exanthema mimicking graft-versus-host disease associated with obstructive lung disease in a non-transplanted patient. Eur J Dermatol (2010) 0.75
Work of Breathing in Fixed and Pressure Relief Continuous Positive Airway Pressure (C-Flex™): A post hoc Analysis. Respiration (2016) 0.75
[Guidelines for diagnosis and therapy of patients with asthma 2005. The most important aspects for adults]. Med Klin (Munich) (2006) 0.75
Association of right ventricular dysfunction and Cheyne-Stokes respiration in patients with chronic heart failure. J Sleep Res (2003) 0.75